Cohen AD et al. Initial clinical activity and safety of BFCR4350A, a FcRH5/CD3 T-cell-engaging bispecific antibody, in relapsed/refractory multiple myeloma. ASH 2020;Abstract 292.
Garfall AL et al. Updated phase 1 results of teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in relapsed and/or refractory multiple myeloma (RRMM). ASH 2020;Abstract 180.
Grosicki S et al. Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): A randomised, open-label, phase 3 trial. Lancet 2020;396(10262):1563-73. Abstract
Kaufman JL et al. Daratumumab (DARA) plus lenalidomide, bortezomib, and dexamethasone (RVd) in patients with transplant-eligible newly diagnosed multiple myeloma (NDMM): Updated analysis of Griffin after 12 months of maintenance therapy. ASH 2020;Abstract 549.
Kumar SK et al. Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): A multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol 2020;21(10):1317-30. Abstract
Kumar SK et al. Updated analysis of daratumumab plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) in patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM): The phase 3 Maia study. ASH 2020;Abstract 2276.
Lonial S et al. DREAMM-2: Single-agent belantamab mafodotin (belamaf) in patients with relapsed/refractory multiple myeloma (RRMM) — 1-year outcomes by prior therapies. ASH 2020;Abstract 1417.
Mateos MV et al. Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): A multicentre, open-label, non-inferiority, randomised, phase 3 trial. Lancet Haematol 2020;7(5):e370-80. Abstract
Munshi NC et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med 2021;384(8):705-16. Abstract
Ocio E et al. ANCHOR (OP-104): Melflufen plus dexamethasone (dex) and daratumumab (dara) or bortezomib (BTZ) in relapsed/refractory multiple myeloma (RRMM) refractory to an IMiD and/or a proteasome inhibitor (PI) — Updated efficacy and safety. ASH 2020;Abstract 417.
Popat R et al. DREAMM-6: Safety, tolerability and clinical activity of belantamab mafodotin (belamaf) in combination with bortezomib/dexamethasone (BorDex) in relapsed/refractory multiple myeloma (RRMM). ASH 2020;Abstract 1419.
Tai Y-T et al. Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Blood 2014;123(20):3128-38. Abstract
van de Donk NWCJ et al. CD38 antibodies in multiple myeloma: Back to the future. Blood 2018;131(1):13-29. Abstract